MediPrint™ Ophthalmics is an emerging pharmaceutical company based in San Diego developing and commercializing a proprietary ocular drug delivery portfolio.

MediPrint™ Ophthalmics

MediPrint Ophthalmics | 539 followers on LinkedIn. Enhancing Vision for Life | Enhancing vision for life with a patented contact lens based drug delivery portfolio.

Corporate Development | Partnerships | Strategic Growth

Sanjeev Ganatra

Director of Quality at MediPrint Ophthalmics

P.N. Balasubramanian

Bruce Holm

Senior Research Fellow

Furqan Maulvi

MediPrint Ophthalmics

Thank you The Medicine Maker for the terrific article about MediPrint Ophthalmics and our founder Praful Doshi . #drugdelivery #contactlenses #glaucoma #enhancingvisionforlife https://lnkd.in/g-n76mSx

Mediprint will be at the American Academy Of Optometry meeting in #Indianapolis November 7-9. We look forward to seeing the optometric community, our partners and clinical colleagues. Certainly reach out to us if you will be attending so we can schedule time to meet. For those attending please make sure to attend the following presentations: Wednesday, November 6th (1:00pm EST) Dr. Walter Whitley and Dr. Justin Schweitzer, OD, FAAO - "Advances in Ocular Drug Delivery" (Indianapolis Convention Center; Room Sagamore 3-5; GO-04) Friday, November 8th (11:30am EST) Dr. I. Ben Gaddie, O.D., F.A.A.O. - "Clinical Successes with Sustained Delivery of Bimatoprost and Hyaluronic Acid from Contact Lenses Using Digital Printing Technology to Manage Glaucoma" (Indianapolis Convention Center; Wabash Ballroom) Part of Drugs, Devices, and New Discoveries: Dive into Optometry’s Evolution and Expansion Praful Doshi David Fancher CBCC Global Research Sanjeev Ganatra #optometry , #drugdelivery , #ophthalmology , #glaucoma , #contactlens MediPrint Ophthalmics #Academy24

We are grateful for being a sponsor at Octane 2024 and are excited for our enhancement of comfort for contact lens wearer in our phase 3 clinical study for sustained delivery for Glaucoma. Check out the video below of our founder and CEO Praful Doshi talking about our product pipeline! #enhancingvisionforlife #glaucoma #contactlenses #helpprotectsight #drugdelivery #ophthalmology #dryeye

We are excited to announce we have successfully completed our Phase 2b Glaucoma Clinical study with positive results. SIGHT-2 study evaluated safety and efficacy of LL-BMT-1 in 28 patients diagnosed with open-angle Glaucoma for three weeks. Results show clinically meaningful and sustained IOP reduction over the duration of 3 weeks which is statistically comparable to 0.01% bimatoprost eye drops. Learn more here: https://lnkd.in/gYVkCsh9 #enhancingvisionforlife #glaucoma #contactlenses #helpprotectsight #drugdelivery #ophthalmology #dryeye

MediPrint is excited to share that Thomas Bender, an industry veteran in the vision care industry, has joined our team as a Strategic Advisor! His extensive expertise will be pivotal in steering the future of our pioneering drug-eluting contact lens technology. Learn more here: https://lnkd.in/g_D-Z9QF #enhancingvisionforlife #glaucoma #contactlenses #helpprotectsight #drugdelivery #ophthalmology #dryeye

Google Maps

Microsoft Exchange Online

Office 365 Mail

Google Maps API

Network Solutions DNS

Network Solutions

CTO, Founder, Chairman

Praful Doshi

Director of Business Development

Niyati Kadakia

Quality

Brandon Huang

Chief Executive Officer

Dan Myers

System Engineer

Tyler Houchin

Founder, President, CTO

Greater San Diego Area Companies With Fewer Than 50 Employees (Top 10K)

Medical Device Early Stage Companies With Fewer Than 1000 Employees

California Early Stage Companies With Less Than $10M in Revenue

West Coast Companies With More Than $1M in Revenue (Top 10K)

MediPrint Ophthalmics (formerly Leo Lens Pharma) is an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight by developing and commercializing a proprietary ocular drug delivery portfolio.

The company was founded in 2001 and is based in San Diego, California, United States.

Series A - MediPrint Ophthalmics

Seed Round - MediPrint Ophthalmics

San Diego

California

United States

North America

MediPrint Ophthalmics Presents Promising Results from Phase 2b Clinical Trial of LL-BMT1 for Glaucoma at American Academy of Optometry

MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive ...

Former CooperVision Leader Tom Bender Joins MediPrint Ophthalmics as Strategic Advisor

MediPrint Ophthalmics Taps Thomas Bender to Propel Ocular Drug Delivery Revolution

Open-Angle Glaucoma Market Size and Share to Accelerate ...

Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key ...

MediPrint Ophthalmics Raises Over $2.5M In Initial Series A Funding

A weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension, designed to provide continuous drug delivery and improve patient compliance.

A proprietary printing technology that allows for the sustained, continuous release of ophthalmic drugs via contact lenses, aimed at treating various eye diseases non-invasively.

Contact lenses that deliver drugs continuously to the eye, offering an alternative to traditional eye drops for conditions like glaucoma, dry eye, and ocular allergies.

news impact assignment basic	general
public peers	general	Nov 19, 2024 5:54 AM	ce26143e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 5:54 AM	65f93c1b
crunchbase trigger	general	Nov 19, 2024 5:54 AM	822fda10
crunchbase profile	general	Nov 19, 2024 11:45 PM	4309e81a
li profile	general	Nov 19, 2024 5:54 AM	8825e568
translate crunchbase fundingrounds	general	Nov 20, 2024 12:30 AM	56d1e4e7
peers	general	Nov 19, 2024 5:54 AM	ec23dd68
news basic	general	Nov 19, 2024 5:54 AM	7d8f2e55
bundesanzeiger	filings
financials download nd	financials
private financials	financials

MEDI

COM:MEDIPRINTLENS

MediPrint™ Ophthalmics